Autonomous Medical Devices, Inc. (AMDI) is at the forefront of next-generation point-of-care testing, emphasizing the integration of advanced microfluidics and protein engineering to enhance diagnostic efficiency. Their focus on cutting-edge microfluidics aims to eliminate delays associated with sample preparation, thereby facilitating quicker diagnostic processes. AMDI's commitment to improving patient outcomes is evident in their development of a 10-minute RT-PCR point-of-care system, which has garnered significant funding through a $5.3 million NIH RAD® Tech Award. This system is designed to provide clinicians with timely PCR testing insights, ultimately reducing healthcare costs while ensuring that patients receive faster diagnoses and treatments.

In addition to their molecular diagnostics, AMDI is leveraging their expertise in protein engineering to develop innovative immunodiagnostic solutions. Their Q-NAb™ IgG Kit exemplifies this approach, offering a fast and quantitative method for detecting neutralizing antibodies against SARS-CoV-2. This kit utilizes Fusion Protein technology to effectively bind non-neutralizing antibodies, allowing for multiplexing capabilities and a wide dynamic range of antibody titers. By employing engineered receptor binding domains, AMDI's assays can simultaneously detect neutralizing antibodies against various SARS-CoV-2 variants, showcasing their commitment to providing the right test for the right patient at the right time.

United States

Autonomous Medical Devices Incorporated (AMDI), with its principal place of business in California, employs a world class team of engineers, scientists, clinicians, and manufacturing experts dedicated to the development and manufacture of point-of-care diagnostic devices using breakthrough microfluidics, protein engineering, and data/cloud connectivity. AMDI will launch its first products from its ISO:13485 certified 110,000 square foot facility in Santa Ana, CA.

Autonomous Medical Devices

Company Details